IntriCon Corporation (NASDAQ: IIN), a medical technology company and major supplier to Medtronic PLC (NYSE: MDT)'s diabetes division, is "one of the more interesting and undiscovered small-cap names" in its sector, according to Stifel.
Analyst Jonathan Block initiated coverage of IntriCon shares with a Buy rating and 12-24-month price target of $35, suggesting 79-percent upside. The stock was added to Stifel's Select List.
IntriCon is a key beneficiary of Medtronic's current and future product cycles, Block said in a Monday note.
The medical division's prospects alone justify 50-percent stock appreciation, the analyst said.
"We see ongoing tailwinds to IntriCon's relationship with Medtronic (81 percent of segment sales) and our 2017-2020 revenue CAGR specific to the Medtronic agreement is 20-percent-plus."
IntriCon is at the forefront of democratizing the $17-billion worldwide hearing market, Block said. The market could be radically changed by favorable legislation that would do away audiologists for recommending hearing aids in the mild-to-moderate segment and possibly allow users to control OTC hearing aids, Block said.
This could occur over the next 12-24 months, the analyst said.
"With IntriCon being the only non-Big 6 manufacturer with an FDA-approved hearing aid coupled with the company's recent investments, IntriCon appears uniquely positioned to capitalize on this very large market opportunity," Block said.
The Price Action
IntriCon shares lost about 1 percent year-to-date through Monday.
The stock was rallying after the upgrade and was up 20.66 percent at the time of publication Tuesday.
JPMorgan Diagnoses The MedTech Space: Stock Picks And Pans
No Fundamental Reason For Boston Scientific Shares' Underperformance, RBC Upgrades Stock
Latest Ratings for IIN
|Apr 2018||Stifel Nicolaus||Initiates Coverage On||Buy|
|Aug 2017||Longbow Research||Downgrades||Buy||Neutral|
|Aug 2014||Dougherty||Initiates Coverage on||Buy|
View More Analyst Ratings for IIN
View the Latest Analyst Ratings
See more from Benzinga
- Longbow Downgrades Texas Roadhouse Ahead Of Q1 Report, Stays Positive On Long-Term Fundamentals
- Molson Coors Downgraded By Goldman Sachs On Weak Volume; Coca-Cola European Partners Upgraded On Growth Opportunity
- Buckingham Sidelined On 'Fully Valued' Netflix After Strong Q1 Print
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.